semaglutide access Medicare is expanding to weight-loss GLP-1 medications. Starting July 1, eligible Medicare beneficiaries can receive GLP-1 Novo Nordisk Expands GLP-1 Access

Some patients receive injections weekly, while others follow a maintenance schedule

Your Semaglutide GLP-1 specialist will help make a plan that will take your own starting weight into account and will have goals to meet while on treatment

Table of Contents Toggle Legal Threats and Regulatory Intervention Forced the Withdrawal Novo Nordisk responded quickly after the announcement, accusing Hims & Hers of illegal mass compounding

The US Preventive Services Task Force recommends screening beginning at age 45 for average-risk individuals, regardless of GLP-1 use

TRIUMPH-4, the first completed Phase 3 trial, showed 28.7% average body weight loss at 68 weeks on retatrutide 12mg versus 2.1% on placebo, as reported by Eli Lilly in December 2025 (peer-reviewed publication pending)